Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic cell vaccine with or without alpha-galactosylceramide for resected melanoma
ACTRN12612001101875Phase 2Active, not recruiting
- Sponsor
- Malaghan Institute of Medical Research
- Start
- Nov 2013
- Modality
- Small Molecules, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine and alpha-galactosylceramide in cutaneous melanoma (CM) (4 arms), sponsored by Malaghan Institute of Medical Research. Primary endpoints: NY-ESO-1 peptide-specific T-cell counts and Influenza peptide-specific T-cell counts. Started Nov 2013; status: active, not recruiting.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccinealpha-galactosylceramide
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on ACTRN12612001101875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001101875.